28,628 Shares in IQVIA Holdings Inc. $IQV Acquired by Meridian Management Co.

Meridian Management Co. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, according to its most recent filing with the SEC. The firm acquired 28,628 shares of the medical research company’s stock, valued at approximately $4,511,000. IQVIA comprises approximately 1.2% of Meridian Management Co.’s holdings, making the stock its 26th largest holding.

Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. Clal Insurance Enterprises Holdings Ltd increased its stake in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after buying an additional 131 shares during the period. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA in the 1st quarter valued at $33,000. Trust Co. of Toledo NA OH acquired a new stake in shares of IQVIA in the 2nd quarter valued at $39,000. J.Safra Asset Management Corp increased its stake in shares of IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after buying an additional 169 shares during the period. Finally, Larson Financial Group LLC increased its stake in shares of IQVIA by 109.9% in the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after buying an additional 144 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Down 0.0%

NYSE:IQV opened at $216.43 on Friday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $225.91. The company has a quick ratio of 0.84, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $36.86 billion, a P/E ratio of 29.69, a P/E/G ratio of 2.43 and a beta of 1.32. The stock’s fifty day simple moving average is $197.12 and its 200-day simple moving average is $173.95.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have recently commented on IQV. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. JPMorgan Chase & Co. lifted their target price on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday. Citigroup raised their price target on IQVIA from $200.00 to $230.00 and gave the stock a “neutral” rating in a research report on Wednesday. Robert W. Baird set a $258.00 price target on IQVIA and gave the stock an “outperform” rating in a research report on Wednesday. Finally, Baird R W upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $241.41.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider directly owned 27,108 shares in the company, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.